Pfizer Combo Therapy Scores Major Win In Prostate Cancer Trial

All NewsMarch 19, 2026

Pfizer (PFE) shares rise as Talzenna/Xtandi combo hits primary goal in Phase 3 prostate cancer trial. See the full TALAPRO-3 results.

Importance Rank:

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

Manage consent